Where does Adlai Nortye Biopharma Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Adlai Nortye Biopharma Co., Ltd. ranks #44,420 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Adlai Nortye Biopharma Co., Ltd. hold?

Adlai Nortye Biopharma Co., Ltd. holds 5 US utility patents granted between 2021 and 2025, spanning 6 technology areas.

What is Adlai Nortye Biopharma Co., Ltd.'s Innovation Score?

Adlai Nortye Biopharma Co., Ltd. has an Innovation Score of 43.3 out of 100 (top 29% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Adlai Nortye Biopharma Co., Ltd. focus on?

Adlai Nortye Biopharma Co., Ltd.'s top technology area is C07D (Heterocyclic Compounds) with 3 patents, ranking #1,866 of 3,165 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Adlai Nortye Biopharma Co., Ltd.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Adlai Nortye Biopharma Co., Ltd..

What does claim depth mean for Adlai Nortye Biopharma Co., Ltd.'s patents?

Adlai Nortye Biopharma Co., Ltd.'s patents average 14.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Adlai Nortye Biopharma Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Adlai Nortye Biopharma Co., Ltd.

USPTO PatentsView assignee record - 5 granted patents across 6 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Adlai ranks #44,420 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 6 technology areas.

#44,420
of 49,997 US assignees by volume: Top 29%
by Innovation Score (43.3/100): 14.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R44420 · Foreign Corporation #44,420 · 5 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 5 grants
LOWER-Q #44,420/49,997
PHOTO-FINISH Adhark
CPC-NARROW C07D · 6 areas
INNOV-PAR 43.3/100
CLAIMS-RICH 14.0 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2021–2025 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Adhark, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Adlai’s 43.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.2 pts (14%) Velocity 20.0 pts (46%) Breadth 8.7 pts (20%) Claim depth 8.4 pts (19%)

Qualcomm Incorporated · highest

85
Adlai Nortye Biopharma · this assignee

43
3D Lighting… · lowest

7

What this shows Adlai's Innovation Score is 43.3/100 (top 29% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Adlai?

Each dot is one of Adlai’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Adlai’s own 14.0 claims/patent is at or below the 15.0 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Adlai vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Adlai's grants concentrate

Adlai Nortye Biopharma Co., Ltd. is a focused PatentsView assignee: 6 CPC subclasses with 60% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2024 (2 grants) versus a trough of 1 in 2021. By volume, Adlai sits between Adhark, Inc. and Advanced Composite Products & Technology, Inc..

Adlai's three-year grant acceleration

Adlai Nortye Biopharma Co., Ltd. shows 3 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Adhark

5
Adhex

5
Adienne

5
Adionics

5
Adolf KÜHNER

5
Advance Lifts

5
Advanced Comfort…

5
Advanced Composit…

5
Adlai Nortye Biop… ◀

5

What this shows Adlai holds 5 patents at rank #44,401, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Adlai

By rank, the assignees closest to #44,401 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Adlai's primary technology class.

Adlai's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 29% higher than 71% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Adlai Nortye Biopharma Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	1	20.0%
2023	1	20.0%
2024	2	40.0%
2025partial year	1	20.0%

Which technologies does Adlai Nortye Biopharma Co., Ltd. patent most?

C07D - Heterocyclic Compounds 3

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 2

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Adlai Nortye Biopharma Co., Ltd.'s patent record in context - here's where to go next.

Adlai Nortye Biopharma Co., Ltd.'s lead technology class is C07D (Heterocyclic Compounds), 60% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #44,420 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Adlai Nortye Biopharma Co., Ltd. against Adhark, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.